YU13200A - Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja - Google Patents

Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Info

Publication number
YU13200A
YU13200A YU13200A YU13200A YU13200A YU 13200 A YU13200 A YU 13200A YU 13200 A YU13200 A YU 13200A YU 13200 A YU13200 A YU 13200A YU 13200 A YU13200 A YU 13200A
Authority
YU
Yugoslavia
Prior art keywords
intermediates
compounds
preparing anti
cancer compounds
hyperproliferate
Prior art date
Application number
YU13200A
Other languages
English (en)
Inventor
Richard Shelton Lehner
Timothy Norris
Dinos Paul Santafianos
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of YU13200A publication Critical patent/YU13200A/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0002—Preliminary treatment
    • C22B15/0004—Preliminary treatment without modification of the copper constituent
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22B—PRODUCTION AND REFINING OF METALS; PRETREATMENT OF RAW MATERIALS
    • C22B15/00—Obtaining copper
    • C22B15/0063—Hydrometallurgy
    • C22B15/0065—Leaching or slurrying
    • C22B15/0067—Leaching or slurrying with acids or salts thereof
    • C22B15/0071—Leaching or slurrying with acids or salts thereof containing sulfur
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P10/00—Technologies related to metal processing
    • Y02P10/20—Recycling

Abstract

Predmetni pronalazak se odnosi na postupke i intermedijere za dobijanje jedinjenja formule I i njihovih farmaceutski prihvatljivih soli i solvata, kao i na strukturno slična jedinjenja, gde R1, R2 i R15 su kao što je definisano ovde. Gornja jedinjenja su primenljiva u tretiranju hiperproliferativnih poremećaja, takvih kao što su kanceri kod sisara.[The subject matter of the invention refers to the process es and intermediates for obtaining of compounds of the formula I and their pharmaceutically acceptable salts and solvates as well as the structurally similar compounds where R1, R2 and R15 are as defined here. The above mentioned compounds are applicable in the treatment of the hyperproliferate disturbances, such as cancers with mammals.
YU13200A 1999-03-31 2000-03-03 Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja YU13200A (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12707299P 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
YU13200A true YU13200A (sh) 2002-10-18

Family

ID=22428179

Family Applications (1)

Application Number Title Priority Date Filing Date
YU13200A YU13200A (sh) 1999-03-31 2000-03-03 Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja

Country Status (50)

Country Link
US (1) US6476040B1 (sh)
EP (1) EP1044969B1 (sh)
JP (2) JP3420549B2 (sh)
KR (2) KR100430210B1 (sh)
CN (2) CN1215061C (sh)
AP (2) AP1265A (sh)
AR (1) AR018705A1 (sh)
AT (1) ATE348098T1 (sh)
AU (2) AU781402B2 (sh)
BG (1) BG65194B1 (sh)
BR (1) BRPI0001486B8 (sh)
CA (2) CA2302965C (sh)
CO (1) CO5160273A1 (sh)
CR (1) CR6165A (sh)
CZ (1) CZ299426B6 (sh)
DE (1) DE60032275T2 (sh)
DK (1) DK1044969T3 (sh)
DZ (1) DZ3030A1 (sh)
EA (3) EA005561B1 (sh)
EE (1) EE04589B1 (sh)
EG (1) EG22506A (sh)
ES (1) ES2278578T3 (sh)
GE (1) GEP20022653B (sh)
GT (1) GT200000037A (sh)
HK (1) HK1029790A1 (sh)
HR (1) HRP20000182B1 (sh)
HU (1) HU227698B1 (sh)
ID (1) ID25427A (sh)
IL (2) IL168036A (sh)
IS (1) IS2468B (sh)
MA (1) MA25087A1 (sh)
MY (1) MY136270A (sh)
NO (2) NO321952B1 (sh)
NZ (2) NZ512818A (sh)
OA (1) OA11335A (sh)
PA (1) PA8491901A1 (sh)
PE (1) PE20001599A1 (sh)
PL (1) PL339330A1 (sh)
PT (1) PT1044969E (sh)
RS (1) RS49836B (sh)
SG (2) SG121687A1 (sh)
SK (1) SK287339B6 (sh)
SV (1) SV2002000047A (sh)
TN (1) TNSN00064A1 (sh)
TR (1) TR200000837A2 (sh)
TW (1) TW553939B (sh)
UA (2) UA80955C2 (sh)
UY (1) UY26086A1 (sh)
YU (1) YU13200A (sh)
ZA (1) ZA200001586B (sh)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
ES2318649T3 (es) 2000-10-20 2009-05-01 EISAI R&D MANAGEMENT CO., LTD. Procedimiento de preparacion de derivados de 4-fenoxi quinolinas.
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7148231B2 (en) 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
US7994159B2 (en) 2003-03-10 2011-08-09 Eisai R&D Management Co., Ltd. c-Kit kinase inhibitor
US8309562B2 (en) * 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2005003100A2 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
SI1667991T1 (sl) 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
CN101337930B (zh) 2003-11-11 2010-09-08 卫材R&D管理有限公司 脲衍生物的制备方法
EP1746999B1 (en) * 2004-05-06 2011-11-16 Warner-Lambert Company LLC 4-phenylamino-quinazolin-6-yl-amides
US8969379B2 (en) 2004-09-17 2015-03-03 Eisai R&D Management Co., Ltd. Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
PL1859793T3 (pl) * 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
US20100105031A1 (en) * 2005-08-01 2010-04-29 Esai R & D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
WO2007052849A1 (ja) * 2005-11-07 2007-05-10 Eisai R & D Management Co., Ltd. 血管新生阻害物質とc-kitキナーゼ阻害物質との併用
US20090247576A1 (en) * 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
CA2652442C (en) 2006-05-18 2014-12-09 Eisai R & D Management Co., Ltd. Antitumor agent for thyroid cancer
JPWO2008001956A1 (ja) * 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
CN101547910A (zh) 2006-07-28 2009-09-30 合成纤维有限公司 结晶埃罗替尼
KR101472600B1 (ko) 2006-08-28 2014-12-15 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암에 대한 항종양제
US8372856B2 (en) 2006-10-27 2013-02-12 Synthon Bv Hydrates of erlotinib hydrochloride
US20100048503A1 (en) 2007-01-19 2010-02-25 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CA2676796C (en) 2007-01-29 2016-02-23 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
PT2170844T (pt) 2007-02-21 2016-08-05 Natco Pharma Ltd Novos polimorfos de cloridrato de erlotinib e método de preparação
KR101441930B1 (ko) 2007-04-04 2014-09-19 시플라 리미티드 에르로티닙 및 그의 약학적으로 허용가능한 염의 제조방법
WO2009002538A2 (en) * 2007-06-25 2008-12-31 Plus Chemicals S.A. Amorphous erlotinib, processes for the preparation thereof, and processes to prepare additional forms of erlotinib
WO2009007984A2 (en) 2007-07-11 2009-01-15 Hetero Drugs Limited An improved process for erlotinib hydrochloride
US20090124642A1 (en) * 2007-08-23 2009-05-14 Augusto Canavesi Crystalline forms of Erlotinib HCI and formulations thereof
WO2009025876A2 (en) * 2007-08-23 2009-02-26 Plus Chemicals, S.A. Crystalline forms of erlotinib hcl and formulations thereof
US20090076042A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched erlotinib
WO2009060945A1 (ja) 2007-11-09 2009-05-14 Eisai R & D Management Co., Ltd. 血管新生阻害物質と抗腫瘍性白金錯体との併用
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
JP2011516426A (ja) * 2008-03-28 2011-05-26 コンサート ファーマシューティカルズ インコーポレイテッド キナゾリン誘導体および治療方法
EP2307386A1 (en) * 2008-07-07 2011-04-13 Plus Chemicals S.A. Crystalline forms of erlotinib base and erlotinib hcl
KR101132937B1 (ko) 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
WO2010040212A1 (en) * 2008-10-08 2010-04-15 Apotex Pharmachem Inc. Processes for the preparation of erlotinib hydrochloride
KR20200137052A (ko) 2009-01-16 2020-12-08 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US20120302749A1 (en) 2009-11-12 2012-11-29 Ranbaxy Laboratories Limited Processes for the preparation of erlotinib hydrochloride form a and erlotinib hydrochloride form b
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US8952022B2 (en) 2010-07-23 2015-02-10 Generics [Uk] Limited Pure erlotinib
IT1402029B1 (it) 2010-10-14 2013-08-28 Italiana Sint Spa Procedimento per la preparazione di erlotinib
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
CN102267952B (zh) * 2011-06-21 2013-12-11 天津市汉康医药生物技术有限公司 喹唑啉类化合物、其制备方法和用途
CN103420924B (zh) * 2012-05-25 2016-08-31 浙江九洲药业股份有限公司 一种盐酸埃罗替尼晶型a的制备方法
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process
CN104755463A (zh) 2012-12-21 2015-07-01 卫材R&D管理有限公司 非晶态形式的喹啉衍生物及其生产方法
WO2014118737A1 (en) 2013-01-31 2014-08-07 Ranbaxy Laboratories Limited Erlotinib salts
MX368099B (es) 2013-05-14 2019-09-19 Eisai R&D Man Co Ltd Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CN103333124B (zh) * 2013-05-28 2015-03-25 埃斯特维华义制药有限公司 一种制备盐酸厄洛替尼晶型f的方法
JO3783B1 (ar) 2014-08-28 2021-01-31 Eisai R&D Man Co Ltd مشتق كوينولين عالي النقاء وطريقة لإنتاجه
CA2908441A1 (en) 2014-10-28 2016-04-28 Cerbios-Pharma Sa Process for the preparation of erlotinib
DK3263106T3 (da) 2015-02-25 2024-01-08 Eisai R&D Man Co Ltd Fremgangsmåde til undertrykkelse af bitterhed af quinolinderivat
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN107801379B (zh) 2015-06-16 2021-05-25 卫材R&D管理有限公司 抗癌剂
CN105884653A (zh) * 2016-06-08 2016-08-24 浙江汇能生物股份有限公司 一种埃罗替尼衍生物及其制备方法
CN106279585A (zh) * 2016-08-26 2017-01-04 宁波圣达精工智能科技有限公司 一种阻燃智能密集书架的制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4747498A (en) * 1986-06-27 1988-05-31 Sunbeam Plastics Corporation Safety dispensing closure-container package
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
EP2295415A1 (en) * 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
TR199801530T2 (xx) 1996-02-13 1998-11-23 Zeneca Limited VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド ４―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6225499B1 (en) 1997-07-14 2001-05-01 Catalytica Pharmaceuticals, Inc. Process for preparing aminoarylacetylenes
AU759691C (en) 1998-04-29 2004-04-29 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4- quinazolinamine mesylate anhydrate and monohydrate

Also Published As

Publication number Publication date
AU2262000A (en) 2000-10-05
SK4442000A3 (en) 2000-10-09
CA2427221A1 (en) 2000-09-30
CZ20001155A3 (cs) 2001-03-14
PT1044969E (pt) 2007-05-31
SV2002000047A (es) 2002-01-23
RS49836B (sr) 2008-08-07
EG22506A (en) 2003-03-31
EP1044969A2 (en) 2000-10-18
AP1655A (en) 2006-09-01
NO20001648L (no) 2000-10-02
EP1044969A3 (en) 2000-11-29
UY26086A1 (es) 2000-10-31
BRPI0001486B1 (pt) 2019-01-29
SK287339B6 (sk) 2010-07-07
DZ3030A1 (fr) 2004-03-27
MY136270A (en) 2008-09-30
NO321952B1 (no) 2006-07-24
HU227698B1 (en) 2011-12-28
OA11335A (en) 2003-12-10
EA200000274A3 (ru) 2003-02-27
CR6165A (es) 2008-10-10
GEP20022653B (en) 2002-03-25
KR20020084903A (ko) 2002-11-13
EA005561B1 (ru) 2005-04-28
JP2000290262A (ja) 2000-10-17
IS5411A (is) 2000-10-02
AR018705A1 (es) 2001-11-28
DK1044969T3 (da) 2007-04-23
CA2427221C (en) 2008-09-16
CZ299426B6 (cs) 2008-07-23
TR200000837A2 (tr) 2000-11-21
KR100430210B1 (ko) 2004-05-03
IS2468B (is) 2008-12-15
EA200201244A1 (ru) 2003-04-24
JP3420549B2 (ja) 2003-06-23
IL135245A0 (en) 2001-05-20
AU781402B2 (en) 2005-05-19
ID25427A (id) 2000-10-05
NO20001648D0 (no) 2000-03-30
CA2302965C (en) 2004-02-17
BG65194B1 (bg) 2007-06-29
AU2005201494B2 (en) 2008-02-07
EA200000274A2 (ru) 2000-10-30
NZ503683A (en) 2001-09-28
KR100430209B1 (ko) 2004-05-03
NZ512818A (en) 2003-01-31
EE04589B1 (et) 2006-02-15
EP1044969B1 (en) 2006-12-13
HUP0001353A3 (en) 2002-01-28
BG104278A (en) 2001-08-31
TW553939B (en) 2003-09-21
EA005892B1 (ru) 2005-06-30
MA25087A1 (fr) 2000-10-01
PA8491901A1 (es) 2001-12-14
JP4074509B2 (ja) 2008-04-09
PL339330A1 (en) 2000-10-09
SG115536A1 (en) 2005-10-28
NO324745B1 (no) 2007-12-03
TNSN00064A1 (fr) 2005-11-10
CN1699350A (zh) 2005-11-23
CO5160273A1 (es) 2002-05-30
CN100351242C (zh) 2007-11-28
HRP20000182B1 (en) 2007-10-31
IL168036A (en) 2006-12-10
GT200000037A (es) 2001-09-21
SG121687A1 (en) 2006-05-26
JP2003176274A (ja) 2003-06-24
ATE348098T1 (de) 2007-01-15
BRPI0001486B8 (pt) 2021-05-25
AP2000001778A0 (en) 2000-03-31
BR0001486A (pt) 2001-05-02
EA200201245A1 (ru) 2003-04-24
EA004654B1 (ru) 2004-06-24
ES2278578T3 (es) 2007-08-16
CA2302965A1 (en) 2000-09-30
US6476040B1 (en) 2002-11-05
PE20001599A1 (es) 2001-01-18
DE60032275T2 (de) 2007-07-12
ZA200001586B (en) 2001-10-01
AU2005201494A1 (en) 2005-05-05
HUP0001353A2 (hu) 2001-05-28
NO20054715L (no) 2000-10-02
HU0001353D0 (en) 2000-06-28
EE200000255A (et) 2000-12-15
HK1029790A1 (en) 2001-04-12
CN1276370A (zh) 2000-12-13
CN1215061C (zh) 2005-08-17
AP1265A (en) 2004-03-26
DE60032275D1 (de) 2007-01-25
KR20010014658A (ko) 2001-02-26
HRP20000182A2 (en) 2001-04-30
UA70928C2 (uk) 2004-11-15
UA80955C2 (en) 2007-11-26

Similar Documents

Publication Publication Date Title
YU13200A (sh) Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
MY124390A (en) Substituted bicyclic derivatives useful as anticancer agents
YU95102A (sh) Supstituisani biciklični derivati u lečenju abnormalnog rasta ćelija
RS20050180A (en) Novel benzoimidazole derivatives useful as antiproliferative agensts
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
NZ519241A (en) Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
TW200500339A (en) Pyrrolidine derivatives, and process for the preparation
GB9923077D0 (en) Sapogenin derivatives and their use
HK1052940A1 (en) Synthetic methods for aplidine and new antitumoralderivatives, methods of making and using them
DE69907419D1 (en) Antitumorwirkstoffe
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
WO2002026720A3 (en) PIPERAZINE BASED INHIBITORS OF FACTOR Xa
HK1055304A1 (en) Tricyclic imidazopyridines
TNSN02096A1 (en) Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
HK1077303A1 (en) Hexacyclic compounds
MX9704203A (es) Utilizacion de derivados de teofilina para el tratamiento y la profilaxis de estados de choque, nuevos compuestos de xantina y procedimiento para su preparacion.
ATE193705T1 (de) 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen- - on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie
MX9601163A (es) Nuevos compuestos derivados de cromeno.
NZ233618A (en) Optionally heterocyclic substituted pyrrolidone derivatives and pharmaceutical compositions
DE60044804D1 (de) Acylderivate des 4-demethylpenclomedins, verwendung und zubereitung derselben
MY120806A (en) Improved process for preparing pharmaceutically valuable norbenzomorphane derivatives.
TW288015B (en) New chromene derivatives
CY1110529T1 (el) Παρασκευη ν-υποκατεστημενων 2,7-διαλκυλο-4-υδροξυ-5-αμινο-8-αρυλοοκτανοϋλαμιδιων